Due to the clinically significant results of PIK3CA inhibitors in metastatic BC patients15 and the spatial heterogeneity of PIK3CA expression within BC (from primary tumor to metastases19), the reliable screening for PIK3CAm is still of paramount importance, as it could guide clinicians' decision making. The gene discussed is PIK3CA; the disease is neoplasm.